m+Medelevator.RU
← Поиск публикаций
Archivos de cardiologia de Mexico · 2026

Outcomes of thoracic endovascular aortic repair. 10-years follow-up in LATAM population: experience from a tertiary care center in Mexico.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Uribe-González Jhonathan, Trujillo-Virgen Erick, Leocachín-Parra Daniela, Montoya-Guerrero Silvestre, Márquez-González Horacio, Campuzano-Madrid Agustín, Arizmendi-Uribe Efraín, Amaro-Balderas Eileen, Campuzano-González Daniel, Estrada-Gallegos Joel

Аннотация

BACKGROUND: Thoracic aortic pathologies comprise a broad group of conditions affecting one or more layers of the aorta, some of which are known to be life-threatening. The development of thoracic aortic endovascular repair (TEVAR) has enabled a minimally invasive approach for treating these cases, with excellent long-term results.

OBJECTIVE: To describe clinical and technical outcomes of patients who underwent thoracic endovascular aortic repair (TEVAR) in a single tertiary care center.

METHOD: An observational, descriptive, retrospective cohort study. We included patients of 18 years-old or older who underwent TEVAR either as a single procedure or as part of a hybrid repair, between 2011 and 2023, in the Cardiology Hospital of the National Medical Centre XXI Century.

RESULTS: A total of 66 patients were included, of whom 77.2% were men. The most frequent cardiovascular risk factors were hypertension and tobacco use. TEVAR was performed as a single procedure in 57.6% (n = 38) and as a hybrid repair in 42.4% (n = 28). Technical success was achieved in 95.4% (n = 63). Event-free survival was 81.8% (n = 54) during hospitalization, 81.5% (n = 54) at 30 days, 76.9% (n = 50) at 1 year, 75.4% (n = 43) at 5 years, and 63.6% (n = 21) at 10 years. Adverse events occurred in 27.2% (n = 18) of cases, most commonly vascular access complications (12.1%, n = 8), spinal cord ischemia (4.5%, n = 3), and reintervention (4.5%, n = 3).

CONCLUSION: In this retrospective single-center experience, TEVAR demonstrated high technical success and acceptable mid- and long-term event-free survival. These findings support the feasibility and effectiveness of TEVAR in a tertiary-level care setting.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты